D121 is a NCE that has a very good potential to treat leishmaniasis, a neglected tropical disease.

We are at the end of phase I. With a very good international team we can take the development further through phase II and III clinical trials. Upon approval of NDA, this molecule is eligible for a Priority Review Voucher.

Interested in receiving an investment proposal for this project? Please fill in the form.

Bioconference San Francisco January 2016

Oblita Therapeutics has participated in the Bioconference in San Francisco (USA) on January 11-13, 2016.

    Your Name (required)

    Name of company/organisation (required)

    Your Email (required)


    Your Message